Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER Studies for Active Psoriatic Arthritis

 Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER Studies for Active Psoriatic Arthritis

Janssen’s Stelara (ustekinumab) Receives the US FDA’s Approval for Moderately to Severely Active Ulcerative Colitis

Shots:

  • The P-III DISCOVER 1 & 2 studies involves assessing of Tremfya (q4w/q8w, SC) vs PBO in 381 & 739 patients with active psoriatic arthritis including those previously treated with biologic anti-TNF alpha agent respectively
  • Collective Results: @24wks. met its 1EPs of ACR20 (59%/52% & 64% vs 22% & 33%); patients with ≥3BSA affected with psoriasis and IGA score of ≥2 at baseline (75%/57% & 69%/71% vs 15% & 19%); showed reduction in radiographic damage progression
  • Tremfya is a mAb targeting p19 subunit of IL-23 and is an approved therapy in the US, Canada, Japan & EU for moderate to severe plaque psoriasis. The sBLA submission to the US FDA on Sept 13, 2019 & EMA’s validation on Oct 11, 2019 is based on the results of P-III DISCOVERY program

Click here to­ read full press release/ article | Ref: PRNewswire | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post